This month, Hoosier Cancer Research Network features our member institution Vanderbilt-Ingram Cancer Center (VICC) in Nashville, Tenn., and Nancy B. Davis, MD, associate professor of medicine and VICC senior medical director for Cancer Care Network and Strategy, Division of Hematology/Oncology, Vanderbilt University Medical Center.

Research Interests and Expertise:

Dr. Davis’ research interests and clinical practice both focus on the treatment of relapsed and metastatic genitourinary cancers, with particular interest in advanced urothelial cancers and penile cancer. She believes strongly in a multidisciplinary clinical application of new diagnostics and therapies to improve outcomes while maintaining quality of life. She is the site principal investigator for HCRN genitourinary studies at Vanderbilt University Medical Center and a member of the HCRN Genitourinary Clinical Trial Working Group.

Educational Background:

• MD: University of Texas Health Science Center, Houston, Texas
• Fellowship: Hematology/Oncology, University of Chicago Medical Center
• Residency: Internal Medicine, University of Chicago Medical Center

Three facts about Dr. Davis:

• She served on active duty in the U.S. Army prior to going to medical school.
• She loves to read, especially regarding medieval history.
• She is originally from a small town in southern New Jersey.

About Hoosier Cancer Research Network:

Hoosier Cancer Research Network (formerly known as Hoosier Oncology Group) conducts innovative cancer research in collaboration with academic and community physicians and scientists across the United States. The organization provides comprehensive clinical trial management and support, from conception through publication. Created in 1984 as a program of the Walther Cancer Institute, Hoosier Cancer Research Network became an independent nonprofit clinical research organization in 2007. Since its founding, Hoosier Cancer Research Network has conducted more than 230 trials in a variety of cancer types and supportive care, resulting in more than 350 publications. More than 9,000 subjects have participated in Hoosier Cancer Research Network clinical trials.